| P50 | author | Daniela E. Matei | Q79322621 |
| P2093 | author name string | Michael S Gordon | |
| | Francisco Robert | |
| | Lee S Rosen | |
| P2860 | cites work | Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions | Q79753668 |
| | Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma | Q79973857 |
| | Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma | Q81192902 |
| | Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy | Q81385868 |
| | Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: Implications in the modulation of cell proliferation | Q81612146 |
| | Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma | Q83151095 |
| | The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count | Q83155632 |
| | Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma | Q24300402 |
| | Modes of resistance to anti-angiogenic therapy | Q24608005 |
| | Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Q24608039 |
| | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement | Q27861120 |
| | Defective angiogenesis in mice lacking endoglin | Q28144833 |
| | Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide | Q28203483 |
| | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 |
| | Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 |
| | Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 |
| | Angiogenesis in health and disease | Q29614541 |
| | Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma | Q29617568 |
| | Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q29620127 |
| | Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts | Q31087014 |
| | Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma | Q33241639 |
| | Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 | Q33813718 |
| | Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival | Q34021957 |
| | Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies | Q34540047 |
| | Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. | Q34579127 |
| | Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Q34633525 |
| | Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial | Q34638316 |
| | Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice | Q35157425 |
| | Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature | Q35201283 |
| | Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth | Q35314203 |
| | Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. | Q35587248 |
| | A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer | Q36205086 |
| | Hereditary Haemorrhagic Telangiectasia (HHT): genetic and molecular aspects. | Q36447285 |
| | Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination | Q36694132 |
| | The VHL/HIF axis in clear cell renal carcinoma | Q36872295 |
| | Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice | Q36941168 |
| | Endoglin (CD105): a marker of tumor vasculature and potential target for therapy | Q37125562 |
| | Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer | Q37214304 |
| | Benign mesenchymal stromal cells in human sarcomas. | Q37287076 |
| | ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours | Q37295765 |
| | Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis | Q37340349 |
| | Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. | Q37404033 |
| | Pathways mediating VEGF-independent tumor angiogenesis | Q37652164 |
| | Endoglin for tumor imaging and targeted cancer therapy. | Q38074721 |
| | In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours | Q39257411 |
| | Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm | Q39747265 |
| | Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. | Q39753483 |
| | Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis | Q40013934 |
| | Sarcoma derived from cultured mesenchymal stem cells | Q40220522 |
| | CD105 prevents apoptosis in hypoxic endothelial cells | Q42441203 |
| | Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways | Q42525897 |
| | CD105 expression is an independent predictor of survival in patients with endometrial cancer | Q43405195 |
| | Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma | Q43625943 |
| | Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy | Q46179881 |
| | Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer | Q46892024 |
| | Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts | Q47594304 |
| | Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. | Q48227582 |
| | Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. | Q48760414 |
| | Endoglin has a crucial role in blood cell-mediated vascular repair. | Q52002581 |
| | Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. | Q53424963 |
| | The prognostic value of endoglin (CD105) expression in ovarian carcinoma. | Q53596396 |
| | Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. | Q53647266 |
| | Identification of a tumor-initiating stem cell population in human renal carcinomas | Q58831537 |
| | Angiogenesis | Q67897095 |
| | Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line | Q68098157 |
| | Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow | Q72169083 |
| | A case of angiosarcoma of the breast | Q73342562 |
| | Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis | Q74462138 |
| | Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies | Q74484401 |
| | Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody | Q77161616 |
| | Expression of transforming growth factor beta and transforming growth factor beta receptors on AIDS-associated Kaposi's sarcoma | Q77555172 |
| | Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy | Q77555510 |
| P433 | issue | 2 | |
| P304 | page(s) | 365 | |
| P577 | publication date | 2014-02-01 | |
| P1433 | published in | Current Oncology Reports | Q2264969 |
| P1476 | title | Endoglin for targeted cancer treatment | |
| P478 | volume | 16 | |